[SCHEDULE 13G/A] Integra LifeSciences Holdings SEC Filing

Rhea-AI Filing Summary

Globe Life Inc. (GL) – Form 4 insider transaction. EVP & Chief Strategy Officer Michael C. Majors exercised 10,000 employee stock options at an exercise price of $100.74 on 08/01/2025, immediately selling 9,991 shares in two open-market trades at a volume-weighted average price of $137.41 (price range $136.79-$137.78). A de-minimis 9 shares were also sold at $137.79.

After the transactions, Majors’ direct share ownership remains 47,066 common shares, unchanged versus the starting balance, implying the sale largely financed the option exercise and tax/cost obligations. He continues to hold 27,000 employee stock options with expiry 02/26/2027. No indirect ownership is reported.

The trades represent roughly 0.05 % of Globe Life’s 97 m basic shares outstanding, a size that is unlikely to affect float or governance dynamics. The Form 4 does not reference any 10b5-1 trading plan, suggesting discretionary timing. No company fundamentals, earnings data, or strategic disclosures accompany this filing; therefore, the filing’s material significance for shareholders is considered low, though some investors may view recurring executive sales as a sentiment datapoint.

Insights

Securities Analyst

TL;DR: Routine option exercise funded by near-simultaneous sale; no net share change, minimal impact on GL valuation.

Majors exercised 10,000 options acquired in 2023, selling almost the same number of shares at $137, roughly 36 % above the strike. The transaction is tax-efficient and leaves his direct stake flat at 47,066 shares—still a meaningful but non-controlling position (<0.05 % of shares outstanding). GL averages ~500 k daily volume; a 10 k share sale is easily absorbed and should not pressure price. Lack of a Rule 10b5-1 notation suggests timing discretion, yet the absence of net selling tempers any bearish signal. Overall, I view the filing as informational, with negligible effect on cash flow, share count, or insider alignment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

INTEGRA LIFESCIENCES HOLDINGS CORP

(Name of Issuer)

Common Stock

(Title of Class of Securities)

457985208

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 457985208

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,286,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,372,686.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,379,401.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.3 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: INTEGRA LIFESCIENCES HOLDINGS CORP
(b)	Address of issuer's principal executive offices: 1100 CAMPUS ROAD, PRINCETON, NJ, 08540
Item 2.
(a)	Name of person filing: Morgan Stanley
(b)	Address or principal business office or, if none, residence: 1585 Broadway, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 457985208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 4.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/05/2025

FAQ

How many Globe Life (GL) shares did EVP Michael C. Majors sell on 08/01/2025?

9,991 shares were sold in two trades, plus an additional 9 shares, for a total of 10,000 shares disposed.

At what price were the Globe Life shares sold?

The weighted average sale price was $137.41 per share, with a range of $136.79–$137.78.

Did the executive’s share ownership in GL change after the transactions?

No. Majors’ direct holdings stayed at 47,066 shares; the sale offset the 10,000-share option exercise.

What is the exercise price and expiry of the options exercised?

Options were exercised at $100.74 and expire on 02/26/2027.

Is this Form 4 likely to impact Globe Life’s stock price?

Given the small size (<0.05 % of shares) and neutral net share change, the market impact is expected to be minimal.